Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00390195 | Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 1 / Phase 2 | 134 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 2, 2009 | clinicaltrials |
| NCT00181506 | HI-CHART:Feasibility of High-Dose Accelerated Conformal Radiotherapy | completed | Phase 1 / Phase 2 | 180 | Maastricht Radiation OncologyOTHER | 1 | Jun 30, 2009 | clinicaltrials |
| NCT00181545 | Safety Study of Individualised Radiation Dose Determination for Lung Cancer Patients. | completed | Phase 1 | 30 | Maastricht Radiation OncologyOTHER | 1 | Jun 30, 2009 | clinicaltrials |
| NCT00690053 | Non-Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PET)(HX-4) | completed | Phase 1 | 12 | Maastricht Radiation OncologyOTHER | 1 | Jun 30, 2009 | clinicaltrials |
| NCT00675727 | Safety Study of CADI-05 in Patients With Advanced Stage Melanoma | terminated | Phase 1 / Phase 2 | 20 | Cadila PharnmaceuticalsINDUSTRY | 1 | Jun 11, 2009 | clinicaltrials |
| NCT00004086 | Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer | unknown | Phase 1 | — | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 9, 2009 | clinicaltrials |
| NCT00344786 | Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | terminated | Phase 1 | 15 | BiogenINDUSTRY | 1 | Jun 5, 2009 | clinicaltrials |
| NCT00113724 | Study of TPI 287 in Patients With Advanced Malignancies | completed | Phase 1 | 48 | Cortice Biosciences, Inc.INDUSTRY | 1 | Jun 4, 2009 | clinicaltrials |
| NCT00032903 | This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma. | completed | Phase 1 / Phase 2 | 59 | Sigma-Tau Research, Inc.INDUSTRY | 1 | Jun 3, 2009 | clinicaltrials |
| NCT00288925 | Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment | completed | Phase 1 / Phase 2 | 30 | Zeria PharmaceuticalINDUSTRY | 1 | Jun 1, 2009 | clinicaltrials |
| NCT00352677 | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | completed | Phase 1 | 100 | CytRxINDUSTRY | 3 | Jun 1, 2009 | clinicaltrials |
| NCT00664170 | A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer | completed | Phase 1 | 39 | Mast Therapeutics, Inc.INDUSTRY | 3 | May 28, 2009 | clinicaltrials |
| NCT00389285 | Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 52 | ZymoGeneticsINDUSTRY | 1 | May 27, 2009 | clinicaltrials |
| NCT00904852 | Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme | withdrawn | Phase 1 | 30 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | May 20, 2009 | clinicaltrials |
| NCT00854854 | Efficacy Study of TKcell in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 94 | BinexINDUSTRY | 1 | May 18, 2009 | clinicaltrials |
| NCT00854971 | Efficacy Study of TKcell in Advanced Colorectal Cancer | unknown | Phase 1 / Phase 2 | 86 | BinexINDUSTRY | 1 | May 18, 2009 | clinicaltrials |
| NCT00543972 | Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia | terminated | Phase 1 | 12 | SanofiINDUSTRY | 3 | May 14, 2009 | clinicaltrials |
| NCT00119600 | A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy | terminated | Phase 1 / Phase 2 | — | AmgenINDUSTRY | 0 | May 11, 2009 | clinicaltrials |
| NCT00733798 | A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma | terminated | Phase 1 / Phase 2 | 58 | TransMolecularINDUSTRY | 1 | May 11, 2009 | clinicaltrials |
| NCT00895466 | Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 12 | Pepscan TherapeuticsINDUSTRY | 1 | May 8, 2009 | clinicaltrials |
| NCT00683358 | Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 14 | Tokyo UniversityOTHER | 1 | May 7, 2009 | clinicaltrials |
| NCT00506402 | A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies | completed | Phase 1 | 30 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | May 5, 2009 | clinicaltrials |
| NCT00096707 | Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 50 | Threshold PharmaceuticalsINDUSTRY | 1 | Apr 29, 2009 | clinicaltrials |
| NCT00890110 | Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib(rcc) | unknown | Phase 1 / Phase 2 | 13 | Hadassah Medical OrganizationOTHER | 0 | Apr 29, 2009 | clinicaltrials |
| NCT00075933 | ARQ 501 in Subjects With Cancer | completed | Phase 1 | 80 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 28, 2009 | clinicaltrials |
| NCT00099190 | ARQ 501 in Combination With Docetaxel in Patients With Cancer | completed | Phase 1 | 50 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 28, 2009 | clinicaltrials |
| NCT00234416 | IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 45 | AstraZenecaINDUSTRY | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00242788 | IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure | completed | Phase 1 / Phase 2 | 40 | AstraZenecaINDUSTRY | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00547404 | Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma | withdrawn | Phase 1 | 35 | Piramal Enterprises LimitedINDUSTRY | 0 | Apr 23, 2009 | clinicaltrials |
| NCT00106626 | Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors | completed | Phase 1 | 52 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 22, 2009 | clinicaltrials |
| NCT00639522 | Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma | unknown | Phase 1 | 18 | Nanjing Sike Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 15, 2009 | clinicaltrials |
| NCT00881816 | Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma | unknown | Phase 1 | 15 | Nanjing Sike Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 15, 2009 | clinicaltrials |
| NCT00185861 | Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma | completed | Phase 1 | 12 | Stanford UniversityOTHER | 1 | Apr 9, 2009 | clinicaltrials |
| NCT00070083 | Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | completed | Phase 1 | — | British Columbia Cancer AgencyOTHER | 2 | Apr 7, 2009 | clinicaltrials |
| NCT00080054 | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | completed | Phase 1 | 24 | Pharmacyclics LLC.INDUSTRY | 1 | Apr 3, 2009 | clinicaltrials |
| NCT00102505 | A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 36 | Pharmacyclics LLC.INDUSTRY | 1 | Apr 3, 2009 | clinicaltrials |
| NCT00379132 | 131-I-TM-601 Study in Adults With Solid Tumors | completed | Phase 1 | 60 | TransMolecularINDUSTRY | 1 | Mar 31, 2009 | clinicaltrials |
| NCT00695851 | Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients. | completed | Phase 1 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 30, 2009 | clinicaltrials |
| NCT00080405 | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 40 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Mar 27, 2009 | clinicaltrials |
| NCT00064584 | Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 24, 2009 | clinicaltrials |
| NCT00459823 | A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours | suspended | Phase 1 | 40 | Eisai LimitedINDUSTRY | 2 | Mar 24, 2009 | clinicaltrials |
| NCT00452257 | A Study of Enzastaurin in Patients With Leukemia | completed | Phase 1 | 18 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 19, 2009 | clinicaltrials |
| NCT00272415 | A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma | terminated | Phase 1 | 39 | Genentech, Inc.INDUSTRY | 0 | Mar 11, 2009 | clinicaltrials |
| NCT00095108 | Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer | completed | Phase 1 | 43 | ZymoGeneticsINDUSTRY | 1 | Mar 9, 2009 | clinicaltrials |
| NCT00533728 | Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma | completed | Phase 1 | 12 | Biotec Pharmacon ASAINDUSTRY | 1 | Mar 4, 2009 | clinicaltrials |
| NCT00006347 | Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | unknown | Phase 1 | — | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Mar 3, 2009 | clinicaltrials |
| NCT00006458 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer | unknown | Phase 1 | — | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Mar 3, 2009 | clinicaltrials |
| NCT00291473 | Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers | completed | Phase 1 | 9 | Ludwig Institute for Cancer ResearchOTHER | 1 | Mar 3, 2009 | clinicaltrials |
| NCT00540332 | A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy | withdrawn | Phase 1 / Phase 2 | 0 | Swedish Orphan BiovitrumINDUSTRY | 0 | Mar 2, 2009 | clinicaltrials |
| NCT00422773 | Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 21 | Technische Universität DresdenOTHER | 1 | Feb 27, 2009 | clinicaltrials |
Data updated 23 days agoSource updated Jul 2, 2009source: clinicaltrials